Abstract

You have accessJournal of UrologyCME1 Apr 2023LBA02-07 SEX-DEPENDENT DISTRIBUTION OF PATHOGENIC GERMLINE VARIANTS IN BLADDER CANCER: A POPULATION-BASED ANALYSIS OF 400,000 INDIVIDUALS Laura Bukavina, Danly Omil-Lima, Laura Davis, Raju Chelluri, Andres Correa, Lee Ponsky, Alexander Kutikov, and Philip Abbosh Laura BukavinaLaura Bukavina More articles by this author , Danly Omil-LimaDanly Omil-Lima More articles by this author , Laura DavisLaura Davis More articles by this author , Raju ChelluriRaju Chelluri More articles by this author , Andres CorreaAndres Correa More articles by this author , Lee PonskyLee Ponsky More articles by this author , Alexander KutikovAlexander Kutikov More articles by this author , and Philip AbboshPhilip Abbosh More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003361.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Characterizing the impact of germline mutational burden on bladder carcinogenesis has been a challenge. Prior studies implicate genes of unknown pathogenicity and lack cross-population comparisons. In the current study, we sought to evaluate the impact of pathogenic germline mutations in a cohort of bladder cancer (BC) patients compared to a large sample of non-cancer controls. METHODS: Using the UK Biobank, a biomedical database containing genetic information on over 500,000 patients from the United Kingdom, we analyzed germline mutations in patients diagnosed with BC. A genome-wide regression approach in REGENIE was used for downstream analysis, combined with individual values for the trait of interest. We restricted our analysis to high and moderate impact variants for initial regression. Utilization of pathologic/likely pathologic (P/LP) germline variants within each respective cohort as defined by REGENIE outputs was then re-defined within each population (BC male/female, CTRL male/female). RESULTS: Of 502,387 database patients, 5,090 were identified with BC and genetic data. Compared to men with BC (n=3744), women with BC (n=1346) exhibited a higher mutational carrier rate (20.4% vs 14.0%, p=0.02, Figure 1A). Males with BC presented with higher rates of P/LP mutations compared to male CTRLs in APC (p=0.019), and RECQL4 (p=0.044). While overall P/LP percentage was higher in females compared to males, no statistically significant difference was seen in specific genes compared to female CTRLs. Despite this, female carriers had younger age at BC diagnosis (56.7yo) compared to women and men without P/LP variants detected, and men with P/LP (62.0, 64.1, and 63.9, respectively; p<0.01; Figure 1B). CONCLUSIONS: Our study demonstrates notable differences in germline mutations between male and female bladder cancer cohorts. Specifically, women were noted to harbor a greater frequency of germline mutations and demonstrated associations between germline mutations and early disease onset not seen in men. Further research is needed to determine the interplay between genetic and environmental factors influencing BC pathogenesis. Such investigations will aid in advancing personalized cancer care. Source of Funding: Society of Women in Urology (SWIU) Elizabeth Pickett Award © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1188 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Laura Bukavina More articles by this author Danly Omil-Lima More articles by this author Laura Davis More articles by this author Raju Chelluri More articles by this author Andres Correa More articles by this author Lee Ponsky More articles by this author Alexander Kutikov More articles by this author Philip Abbosh More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.